Medpace (NASDAQ:MEDP) Updates FY 2026 Earnings Guidance

Medpace (NASDAQ:MEDP) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 17.250-17.950 for the period, compared to the consensus estimate of 17.070. The company issued revenue guidance of $2.8 billion-$2.9 billion, compared to the consensus revenue estimate of $2.8 billion.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on MEDP shares. Royal Bank Of Canada reduced their price target on Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. BMO Capital Markets cut their target price on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a research report on Friday, April 24th. Robert W. Baird reiterated a “neutral” rating and set a $547.00 target price (up from $477.00) on shares of Medpace in a research report on Wednesday, July 8th. Mizuho raised their price target on shares of Medpace from $495.00 to $586.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Medpace in a report on Thursday, July 2nd. Two research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $469.50.

Medpace Stock Performance

Shares of MEDP stock traded down $3.55 during trading hours on Wednesday, hitting $528.12. 482,935 shares of the company were exchanged, compared to its average volume of 350,959. The firm has a market cap of $15.08 billion, a P/E ratio of 33.19, a P/E/G ratio of 2.64 and a beta of 1.15. The company has a 50 day simple moving average of $482.55 and a two-hundred day simple moving average of $493.73. Medpace has a fifty-two week low of $373.00 and a fifty-two week high of $628.92.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The business had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.53 million. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, sell-side analysts expect that Medpace will post 17.04 EPS for the current fiscal year.

Insider Activity

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of the business’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the sale, the general counsel owned 20,343 shares in the company, valued at approximately $9,154,350. The trade was a 44.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 20.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Medpace

A number of hedge funds have recently bought and sold shares of MEDP. Quarry LP bought a new position in shares of Medpace during the third quarter valued at about $35,000. Geneos Wealth Management Inc. lifted its holdings in Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after acquiring an additional 37 shares during the period. Greenline Wealth Management LLC purchased a new position in Medpace in the fourth quarter worth $55,000. Group One Trading LLC boosted its holdings in shares of Medpace by 120.0% in the 4th quarter. Group One Trading LLC now owns 100 shares of the company’s stock worth $56,000 after buying an additional 600 shares during the last quarter. Finally, Johnson Financial Group Inc. grew its position in shares of Medpace by 115.7% during the 3rd quarter. Johnson Financial Group Inc. now owns 110 shares of the company’s stock valued at $57,000 after acquiring an additional 59 shares during the period. 77.98% of the stock is owned by hedge funds and other institutional investors.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.